Source comparison
TB-500 Pharmacokinetics: Administration Route Comparison
Subcutaneous (abdominal) 2–4 hours >95% 10–20 hours (alpha), 24–48 hours (beta) Gradual tissue accumulation; sustained therapeutic window Preferred for sustained tissue repair protocols. Allows twice-weekly dosing with stable plasma levels Subcutaneous (deltoi
This comparison does not assign a generated winner or score.
- Subcutaneous (abdominal)
- 2–4 hours
- >95%
- 10–20 hours (alpha), 24–48 hours (beta)
- Gradual tissue accumulation; sustained therapeutic window
- Preferred for sustained tissue repair protocols. Allows twice-weekly dosing with stable plasma levels
- Subcutaneous (deltoid/gluteal)
- 3–5 hours
- 85–90%
- 12–22 hours (alpha), 28–52 hours (beta)
- Slower absorption due to reduced capillary density; similar distribution pattern once absorbed
- Acceptable alternative when abdominal sites unavailable; requires awareness of delayed onset
- Intravenous bolus
- Immediate (0 hours)
- 100%
- 8–16 hours (alpha), 20–40 hours (beta)
- Rapid plasma spike followed by fast redistribution; shorter therapeutic window
- Useful for acute injury models requiring immediate Cmax; not ideal for chronic repair due to rapid clearance
- Intramuscular
- 1–3 hours
- 80–85%
- 10–18 hours (alpha), 24–46 hours (beta)
- Higher local muscle concentration at injection site; uneven systemic distribution
- Limited utility. Local depot effect doesn't align with TB-500's systemic actin-binding mechanism